Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
Phase observationalN = 483
- Population
- Patients with newly diagnosed chronic-phase CML: 271 received imatinib, 105 nilotinib and 107 dasatinib
- Design
- Cohort analysis of patients with chronic-phase CML enrolled in six consecutive or parallel prospective TKI trials at a single institution (MD Anderson Cancer Center) between 30 July 2000 and 17 September 2012. Overall survival by the Kaplan-Meier method was compared with general-population survival from national vital statistics, matched on age, sex, ethnicity and year at diagnosis.
- Arms
- Trial cohort (experimental, n = 483): First-line imatinib (271), nilotinib (105) or dasatinib (107) in prospective trials
- People
- Sasaki K, senior author Cortes JE
Show the numbers
| Endpoint | Analysis | Trial cohort | Control | Effect |
|---|---|---|---|---|
| 5-year relative survivalAll 483 patients with chronic-phase CML in the six trials5-year overall survival of the cohort relative to a matched general population (age, sex, ethnicity, year at diagnosis) | finalmedian follow-up 99.4 monthsSasaki 2015 | 94.7% (92.1–97.4%) | — | The abstract prints the interval as '95% 92.1-97.4' (the word 'CI' is missing); the open author manuscript (PMC4884053) prints the same figure as 94.7% (95% CI 92.1-97.4), so it is a 95% interval. Median follow-up 99.4 months (IQR 44.9 to 121.6); 53 patients (11%) had died. Most common causes of death: progression to advanced stage including transplant complications (17 patients, 4%), secondary malignancies (9, 2%) and cardiovascular causes (9, 2%). Most patients were younger than 65 years and none was older than 85. 5-year survival decreased in older age categories; people with complete cytogenetic response or deeper within 1 year had 5-year survival similar to the general population (figures not given in the abstract). |
| Endpoint | Analysis | Trial cohort | Control | Effect |
|---|---|---|---|---|
| 5-year relative survivalAll 483 patients with chronic-phase CML in the six trials5-year overall survival of the cohort relative to a matched general population (age, sex, ethnicity, year at diagnosis) | finalmedian follow-up 99.4 monthsSasaki 2015 | 94.7% (92.1–97.4%) | — | The abstract prints the interval as '95% 92.1-97.4' (the word 'CI' is missing); the open author manuscript (PMC4884053) prints the same figure as 94.7% (95% CI 92.1-97.4), so it is a 95% interval. Median follow-up 99.4 months (IQR 44.9 to 121.6); 53 patients (11%) had died. Most common causes of death: progression to advanced stage including transplant complications (17 patients, 4%), secondary malignancies (9, 2%) and cardiovascular causes (9, 2%). Most patients were younger than 65 years and none was older than 85. 5-year survival decreased in older age categories; people with complete cytogenetic response or deeper within 1 year had 5-year survival similar to the general population (figures not given in the abstract). |